The HER2 extracellular domain (ECD) can be released by proteolytic cleavage by tissue metalloproteinases [31] and thereby shed into the circulation. Negative 0/1+ None, or weak incomplete membrane ...

Comprehensive characterization of therapeutic monoclonal antibody (mAb) structures is critical for drug development but remains challenging due to the inherent structural heterogeneity. In this study, ...

Hong Kong — Integrated energy company Semirara Mining and Power Corporation (SMPC) has been honored as a Gold medallist at the 25th Asia’s Best Companies Poll, hosted by regional business publication ...

SMPC maintained that it remains exempt from such charges under Presidential Decree 972 of the Coal Development Act of 1976 and its Coal Operating Contract, which prevail over general laws and are ...

A key growth driver of the herceptin market going forward is the increasing incidence of breast cancer, particularly HER2-positive cases. As more people are diagnosed with this type of cancer due to ...

The robust growth of the herceptin market is projected to continue strongly, reaching a milestone of $7.55 billion in 2025, from $7.10 billion in 2024, at a compound annual growth rate CAGR of 6.4%.

The maker of breast cancer drug Herceptin has applied for a licence for it to be used to treat the early stages of the disease. Manufacturer Roche claims its research shows the drug halves the risk of ...

Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to treat breast cancer whose tumour has tested positive to HER2. For more information, see Section 1.

The NHS's drugs watchdog says people with early stage breast cancer should be able to get the drug Herceptin. The draft guidance from the National Institute for Health and Clinical Excellence (NICE) ...

Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...